Chronic Periodontitis
Conditions
Keywords
saliva, omega-3
Brief summary
The investigators primary objective in this clinical intervention study, therefore, was to explore the impact of omega-3 PUFAs in conjunction with scaling and root planing on salivary markers (in patients with chronic periodontitis.
Detailed description
Thirty systemically healthy subjects with chronic periodontitis were enrolled and randomly allocated into two groups. The control group (n=15) was treated with scaling and root planing (SRP)+placebo whereas the test group (n=15) was treated with SRP and dietary supplementation of low-dose omega-3 PUFAs (6.25 mg EPA and 19.19 mg DHA). Clinical parameters were taken at baseline, 1, 3 and 6 months following therapy. Saliva samples were obtained at the same time intervals and analyzed for tumor necrosis factor-α (TNF-α) and superoxide dismutase (SOD).
Interventions
PROCEDUREPlacebo
placebo drug identical except for the fish oil supplement, were only performed at baseline.
PROCEDUREOmega-3
omega-3 PUFAs supplement, were only performed at baseline.
PROCEDURESRP
Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
Sponsors
İlker KESKINER
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* patients diagnosed with chronic periodontitis * had at least nine posterior teeth (not including third molars and teeth with bridges and crowns) * with 5-7 mm pocket depth * three teeth with 6 mm or more of probing attachment loss enrolled in the study
Exclusion criteria
* patients were excluded on the basis of periodontal surgery within the last year; * SRP as part of initial periodontal therapy within the past 6 months; * history of diabetes, any diseases or disorders that compromise wound healing, any history of acute or chronic inflammatory disease, * any oral mucosal inflammatory condition (e.g., aphthous, lichen planus, leukoplakia, and oral cancer) and use of aspirin * other non-steroidal anti-inflammatory drugs or antibiotics within the last 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in levels of salivary TNF alpha | From baseline to 1, 3, 6 months |
Secondary
| Measure | Time frame |
|---|---|
| change in levels of salivary SOD | From baseline to 1, 3, 6 months |
Outcome results
None listed